Skip to main content

Investor Relations

IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Our approach integrates capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from our targeted therapies.

Ideaya Highlights

 
Investor Presentation
Recent News
Dec 6, 2024

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on December 2, 2024, the...

Dec 2, 2024

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor...

Nov 29, 2024

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on November 27, 2024, the...

All Releases

Events
Monday, December 16, 2024
8:00am EST

Pre-registration is available through the following link: https://lifescievents.com/event/ideaya-4/

Wednesday, December 4, 2024
1:20pm EST

Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Jonathan Miller, Managing Director, Biotech and Pharma Equity Research

All Events

Stock Info
NASDAQIDYA

Stock Information

Investor Contact

Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
650-443-6214
investor@ideayabio.com

Subscribe to email alerts
* Required Fields
WE ARE DEDICATED TO

Improving Lives Through Transformative Precision Medicines

INVESTOR INSIGHTS

Close Menu